Virtual-Ligand-Assisted Screening Strategy to Discover Enabling Ligands for Transition Metal Catalysis

The ligand screening process, in which an optimal ligand for a reaction of interest is identified from an enormous and diverse set of candidate molecules, is of particular importance in the development of transition metal catalysis. Conventionally, this process has been performed by experimental trial-and-error cycles, which require significant time and resources. Herein, we report a novel strategy called “virtual-ligand-assisted (VLA) screening” that enables practical in silico ligand screening based on the transition state theory. We developed a virtual ligand, PCl*3, which parameterizes both the electronic and steric effects of monodentate phosphorus(III) ligands in quantum chemical calculations, and used it to assess how these effects perturb the energy profile of a reaction. This parameter-based ligand screening approach allowed us to identify the optimal electronic and steric effects for a reaction of interest, thereby affording guiding principles for rational ligand design. The VLA screening strategy was demonstrated for the selectivity-determining step of the rhodium-catalyzed hydroformylation of a terminal olefin, and phosphorus(III) ligands with potentially high linear or branched selectivities were designed. These findings indicate that VLA screening is a promising approach for streamlining the ligand screening process.

Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications

Proteolysis Targeting Chimeras (PROTACs), heterobifunctional compounds that consist of protein-targeting ligands linked to an E3 ligase recruiter, have arisen as a powerful therapeutic modality for targeted protein degradation (TPD). Despite the popularity of TPD approaches in drug discovery, only a small number of E3 ligase recruiters are available for the >600 E3 ligases that exist in human cells. Here, we have discovered a cysteine-reactive covalent ligand, EN106, that targets FEM1B, an E3 ligase recently discovered as the critical component of the cellular response to reductive stress. By targeting Cys186 in FEM1B, EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1. We further establish that EN106 can be used as a covalent recruiter for FEM1B in TPD applications, in which we demonstrate that a PROTAC linking EN106 to the BET Bromodomain inhibitor JQ1 leads to specific FEM1B- and proteasome-dependent degradation of BRD4 in cells. Our study showcases a covalent ligand that targets a natural E3 ligase-substrate binding site and highlights the utility of covalent ligand screening in expanding the arsenal of E3 ligase recruiters that can be deployed for TPD applications.